Antiphospholipid Syndrome – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Antiphospholipid Syndrome – Drugs In Development, 2024 report and make more profitable business decisions.
Antiphospholipid syndrome (APS) is known also Hughes syndrome. It is an autoimmune disorder characterized by an increased tendency to form abnormal blood clots (thromboses) that can block blood vessels. In APS, the immune system produces abnormal antiphospholipid antibodies that target proteins attached to fat molecules. For diagnosis of antiphospholipid syndrome, the antibodies must appear in blood at least twice, in tests conducted 12 or more weeks apart. Heparin and warfarin are commonly used to treat APS.
The Antiphospholipid Syndrome drugs in development market research report provide comprehensive information on the therapeutics under development for Antiphospholipid Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Antiphospholipid Syndrome and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Antiphospholipid Syndrome | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 10 molecules, with 7 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Antiphospholipid Syndrome therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Antiphospholipid Syndrome pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Antiphospholipid Syndrome treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Akari Therapeutics PlcAURA Biopharm AS
Austhera BioSciences Inc
Beth Israel Deaconess Medical Center
Cadrenal Therapeutics Inc
Johnson & Johnson
KeyMed Biosciences Inc
RemeGen Co Ltd
University College London
University Hospital of Angers
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Antiphospholipid Syndrome reports